BACKGROUND: The worldwide prevalences of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) are estimated to range from 30 to 40 % and 5-17 %, respectively. Hepatocellular carcinoma (HCC) is primarily caused by hepatitis B infection, but retrospective data suggest that 4-29 % of NASH cases will progress to HCC. Currently the connection between NASH and HCC is unclear. AIMS: The purpose of this study was to identify changes in expression of HCC-related genes and metabolite profiles in NAFLD progression. METHODS: Transcriptomic and metabolomic datasets from human liver tissue representing NAFLD progression (normal, steatosis, NASH) were utilized and compared to published data for HCC. RESULTS: Genes involved in Wnt signaling were downregulated in NASH but have been reported to be upregulated in HCC. Extracellular matrix/angiogenesis genes were upregulated in NASH, similar to reports in HCC. Iron homeostasis is known to be perturbed in HCC and we observed downregulation of genes in this pathway. In the metabolomics analysis of hepatic NAFLD samples, several changes were opposite to what has been reported in plasma of HCC patients (lysine, phenylalanine, citrulline, creatine, creatinine, glycodeoxycholic acid, inosine, and alpha-ketoglutarate). In contrast, multiple acyl-lyso-phosphatidylcholine metabolites were downregulated in NASH livers, consistent with observations in HCC patient plasma. CONCLUSIONS: These data indicate an overlap in the pathogenesis of NAFLD and HCC where several classes of HCC related genes and metabolites are altered in NAFLD. Importantly, Wnt signaling and several metabolites are different, thus implicating these genes and metabolites as mediators in the transition from NASH to HCC.
BACKGROUND: The worldwide prevalences of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) are estimated to range from 30 to 40 % and 5-17 %, respectively. Hepatocellular carcinoma (HCC) is primarily caused by hepatitis B infection, but retrospective data suggest that 4-29 % of NASH cases will progress to HCC. Currently the connection between NASH and HCC is unclear. AIMS: The purpose of this study was to identify changes in expression of HCC-related genes and metabolite profiles in NAFLD progression. METHODS: Transcriptomic and metabolomic datasets from human liver tissue representing NAFLD progression (normal, steatosis, NASH) were utilized and compared to published data for HCC. RESULTS: Genes involved in Wnt signaling were downregulated in NASH but have been reported to be upregulated in HCC. Extracellular matrix/angiogenesis genes were upregulated in NASH, similar to reports in HCC. Iron homeostasis is known to be perturbed in HCC and we observed downregulation of genes in this pathway. In the metabolomics analysis of hepatic NAFLD samples, several changes were opposite to what has been reported in plasma of HCC patients (lysine, phenylalanine, citrulline, creatine, creatinine, glycodeoxycholic acid, inosine, and alpha-ketoglutarate). In contrast, multiple acyl-lyso-phosphatidylcholine metabolites were downregulated in NASH livers, consistent with observations in HCC patient plasma. CONCLUSIONS: These data indicate an overlap in the pathogenesis of NAFLD and HCC where several classes of HCC related genes and metabolites are altered in NAFLD. Importantly, Wnt signaling and several metabolites are different, thus implicating these genes and metabolites as mediators in the transition from NASH to HCC.
Authors: Roberta Pang; John Yuen; Man Fung Yuen; Ching Lung Lai; Terence K W Lee; Kwan Man; Ronnie T P Poon; Sheung Tat Fan; Chun M Wong; Irene O L Ng; Yok Lam Kwong; Eric Tse Journal: Oncogene Date: 2004-05-20 Impact factor: 9.867
Authors: Andrew D Patterson; Olivier Maurhofer; Diren Beyoglu; Christian Lanz; Kristopher W Krausz; Thomas Pabst; Frank J Gonzalez; Jean-François Dufour; Jeffrey R Idle Journal: Cancer Res Date: 2011-09-07 Impact factor: 12.701
Authors: Vlad Ratziu; Luminita Bonyhay; Vincent Di Martino; Frederic Charlotte; Lucas Cavallaro; Marie-Hélène Sayegh-Tainturier; Philippe Giral; André Grimaldi; Pierre Opolon; Thierry Poynard Journal: Hepatology Date: 2002-06 Impact factor: 17.425
Authors: April D Lake; Petr Novak; Craig D Fisher; Jonathan P Jackson; Rhiannon N Hardwick; D Dean Billheimer; Walter T Klimecki; Nathan J Cherrington Journal: Drug Metab Dispos Date: 2011-07-07 Impact factor: 3.922
Authors: Philippe Lefebvre; Fanny Lalloyer; Eric Baugé; Michal Pawlak; Céline Gheeraert; Hélène Dehondt; Jonathan Vanhoutte; Eloise Woitrain; Nathalie Hennuyer; Claire Mazuy; Marie Bobowski-Gérard; Francesco Paolo Zummo; Bruno Derudas; Ann Driessen; Guy Hubens; Luisa Vonghia; Wilhelmus J Kwanten; Peter Michielsen; Thomas Vanwolleghem; Jérôme Eeckhoute; An Verrijken; Luc Van Gaal; Sven Francque; Bart Staels Journal: JCI Insight Date: 2017-07-06
Authors: Jessie Qiaoyi Liang; Narcissus Teoh; Lixia Xu; Sharon Pok; Xiangchun Li; Eagle S H Chu; Jonathan Chiu; Ling Dong; Evi Arfianti; W Geoffrey Haigh; Matthew M Yeh; George N Ioannou; Joseph J Y Sung; Geoffrey Farrell; Jun Yu Journal: Nat Commun Date: 2018-10-26 Impact factor: 14.919